The overall response rate was 100% one month after treatment. PeproMene Bio has completed the first dose cohort of its Phase I clinical trial of PMB-CT01, a BAFFR...

The dose escalation trial will assess the biopharma’s SFK inhibitor candidate NXP900. Nuvectis Pharma will test its solid tumour treatment candidate for the first...

The relative change in body weight at 48 weeks compared to baseline is the primary endpoint of the study. Altimmune has completed dosing the last subject in its P...

The vaccine provided durable protection against the rabies virus in preclinical studies. Replicate Bioscience has dosed the first patient in a Phase I clinical tr...

Johnson & Johnson’s Rybrevant is currently approved for a tiny non-small cell lung cancer (NSCLC) niche. A late-stage study could move the drug to a larger disea...

Royalty Pharma, a company known for ponying up chunks of cash in exchange for long-term drug royalties, has hopped on board with Ascendis Pharma's long-acting g...

AstraZeneca’s Ultomiris expansion plan has hit a snag in the U.S. Wednesday, AstraZeneca said the FDA handed the company a complete response letter for its Ultomi...

A technical flaw has resulted in “unauthorized access” to personal information at Johnson & Johnson’s Janssen CarePath patient assistance program, IBM reported o...

Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Outlook Therapeutics has been trying to get an off...